TLANDO Drug Patent Profile

When do Tlando patents expire, and what generic alternatives are available?

Tlando is a drug marketed by Verity and is included in one NDA. There are fourteen patents protecting this drug.

This drug has thirty-eight patent family members in sixteen countries.

The generic ingredient in TLANDO is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tlando

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 8, 2029. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for TLANDO

International Patents:	38
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	1
Patent Applications:	1,651
Drug Prices:	Drug price information for TLANDO
What excipients (inactive ingredients) are in TLANDO?	TLANDO excipients list
DailyMed Link:	TLANDO at DailyMed

See drug prices for TLANDO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TLANDO

NDA:

208088

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TLANDO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lipocine Inc.	Phase 3

See all TLANDO clinical trials

Pharmacology for TLANDO

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

US Patents and Regulatory Information for TLANDO

TLANDO is protected by fifteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes
Verity	TLANDO	testosterone undecanoate	CAPSULE;ORAL	208088-001	Mar 28, 2022		RX	Yes	Yes

International Patents for TLANDO

When does loss-of-exclusivity occur for TLANDO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Russian Federation

South Africa

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TLANDO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012075081
Argentina	095538
Australia	2010203457
Australia	2014232475
Australia	2019200097

TLANDO market dynamics and financial trajectory: revenue drivers, pricing pressures, payer access, and exclusivity-to-generic timing

Last updated: July 22, 2026

TLANDO (tadalafil; oral capsule for benign prostatic hyperplasia and erectile dysfunction) sits at the intersection of high-volume PDE5-inhibitor demand and persistent payer pressure on brand spend. Its financial trajectory is shaped less by clinical differentiation and more by (1) substitution risk versus branded and generic tadalafil products, (2) formulary placement and rebate mechanics, and (3) patent and exclusivity headwinds for “tadalafil-only” brands as generic manufacturing supply expands.

Because TLANDO is a tadalafil-based product, its market ceiling tracks the overall tadalafil franchise dynamics: share is won and lost through access, not through incremental efficacy claims that shift utilization.

---

What is TLANDO and what market does it compete in?

TLANDO is marketed as a PDE5 inhibitor in the BPH and erectile dysfunction (ED) therapeutic areas. In the US, these segments are dominated by tadalafil and sildenafil brands and generics, with payer formularies typically tiering based on step therapy and total cost.

Key competitive substitutes

• Other tadalafil formulations/brands (where available by plan)
• Sildenafil immediate release and sildenafil ER (as covered, often generics)
• Combination products and adjunct ED therapies depending on formulary design
• Generic tadalafil, which anchors price expectations for the molecule class

Where TLANDO fits on payer decision trees

• Plans look for either:
  • the lowest net cost PDE5 inhibitor option, or
  • preferred access with rebate-funded parity against generics
• For BPH/ED, utilization is influenced by:
  • clinician prescribing habits,
  • adherence to chronic dosing,
  • whether the plan treats the product as a preferred ED therapy or forces step edits

---

How do payer dynamics drive TLANDO’s revenue trajectory?

Featured snippet answer: TLANDO revenue tracks net pricing after rebates and formulary position more than list price because the tadalafil class faces sustained generic substitution.

Rebate and access mechanics

• US commercial growth for branded niche or line-extension brands is typically constrained by:
  • formulary “preferred” placement for lowest net cost alternatives,
  • utilization management (step edits, prior authorization for nonpreferred products),
  • class-wide contracting behavior tied to market share targets.
• As generic tadalafil supply tightens less and more SKUs become available, net pricing pressure tends to increase for brands without robust patent protection of the exact formulation/dosing regimen.

Medicare dynamics

• Under Part D, plan formularies and pharmacy benefit managers shift selection toward lowest-cost options after annual formulary updates.
• In Part D, branded volume can plateau if a generic is treated as the preferred tier and TLANDO is placed on a higher cost share tier.

---

What is the exclusivity and patent landscape risk for TLANDO?

Featured snippet answer: TLANDO’s molecule-level vulnerability increases as generic tadalafil availability expands; brand differentiation depends on formulation, method-of-use, or dosing regimen protections rather than tadalafil itself.

How to assess TLANDO’s “real” exclusivity

For a tadalafil brand, exclusivity risk usually comes from three paths:

1. Composition-of-matter and formulation patents (protecting specific dosage forms, coatings, release profiles, or stability approaches)
2. Method-of-use patents (protecting labeled use timing, titration strategies, or specific patient populations)
3. Regulatory exclusivity tied to first approval or supplemental approvals (harder to sustain beyond defined windows)

Orange Book-driven risk model (what matters commercially)

• If the Orange Book for TLANDO lists patents that are:
  • few in number, and
  • close to expiration, generic substitution becomes a sharper forecasting variable for gross-to-net compression.
• If TLANDO’s listed patents include formulation or method-of-use protection extending beyond main composition coverage, generic launch timing can be delayed and contract leverage can persist.

(No Orange Book patent list, expiration dates, or FDA exclusivity periods were provided in the prompt, so a quantified patent-to-revenue timeline cannot be stated.)

---

When do TLANDO revenue projections typically shift due to generic entry?

Featured snippet answer: Revenue usually bends downward first via plan behavior (widening preferred-tier preference for generics) and later via realized volume loss after generic substitution becomes broadly available.

Generic entry impact staging

1. Pre-launch forecasting window
   • Payers tighten contracting with branded manufacturers.
   • PBMs anticipate post-launch pricing and push step edits.
2. Launch and early quarter dynamics
   • Switch rates accelerate where pharmacy claims show immediate generic substitution.
   • Net prices for the brand often compress even before volume drops materially.
3. Maturity
   • Continued volume displacement occurs via:
     • automatic substitution,
     • increased generic share in the channel,
     • reduced brand access in formulary updates.

Financial effects to model

• Gross-to-net compression (rebate increases to defend tier placement)
• Market share loss to generics (claims volume displacement)
• Higher marketing and contracting spend to maintain access
• Reduced payer willingness to cover premium indications or dosing variants if not patent-protected

---

What formulations and lifecycle strategies matter for TLANDO’s competitive durability?

Featured snippet answer: In tadalafil-class markets, lifecycle durability comes from how well a brand protects the specific product attributes and maintains clinician/payer habit around those attributes.

Lifecycle levers

• Dosage form differentiation (coating, release profile, stability)
• Patient adherence positioning (once-daily convenience narratives, where applicable)
• Labeling expansion or supplemental indications (if supported by regulatory history)
• Contracting to secure formulary placement against class-wide lowest-cost options

Manufacturing and supply

• Branded revenue stability is influenced by:
  • uninterrupted supply,
  • allocation handling,
  • ability to support contracting commitments tied to forecasted demand.

---

How does TLANDO compare with competing tadalafil products in market access and pricing pressure?

Featured snippet answer: TLANDO’s advantage is primarily access-related; its molecule competes in a space where generics set the pricing floor.

Competitive comparison dimensions

• Formulary tiering: preferred vs nonpreferred placement drives net unit demand
• Utilization management: prior authorization and step therapy can slow switching
• Patient out-of-pocket: co-pay cards and rebate structures can maintain adherence but often face pushback as generics expand
• Channel contracts: wholesaler and PBM rebates determine net revenue per unit, not list price

How to interpret brand vs generic performance in filings

Look for:

• declining net sales per unit despite stable volume (rebate pressure),
• promotional spend intensity rising without volume gains,
• payer mix shifting toward Medicare where cost-sharing tends to accelerate generic switching.

---

What FDA regulatory status and pathway risks affect TLANDO?

Featured snippet answer: Regulatory risk is mostly indirect for a branded PDE5 inhibitor; the main driver is whether competitors can obtain approval for generic or AB-rated products that substitute at the pharmacy.

Approval pathway implications

• Generic approval depends on:
  • bioequivalence,
  • Orange Book patent carve-outs if patent protection remains in effect,
  • and potential Paragraph IV litigation outcomes.
• Any regulatory approval that bypasses remaining patent barriers can trigger substitution and downward revenue pressure.

(No FDA dossier or ANDA/BLA status details were provided in the prompt, so this section cannot be quantified for TLANDO specifically.)

---

What patent litigation and Paragraph IV challenges could threaten TLANDO?

Featured snippet answer: The largest commercial threat to a tadalafil brand comes from Paragraph IV filings that produce an early generic market entry, forcing tier repositioning and net price compression.

Litigation mechanics that move financials

• Automatic stay can delay generic launches if patents are asserted and the dispute schedule triggers statutory timelines.
• Settlement agreements can:
  • specify entry dates,
  • include payment or supply provisions,
  • and control labeling carve-outs.
• Adverse rulings can enable earlier launches and accelerate revenue declines.

(No TLANDO-specific litigation docket details, settlements, or dates were provided, so no case-specific schedule can be stated.)

---

What is TLANDO’s commercial trajectory: revenue drivers and constraints?

Featured snippet answer: For PDE5 inhibitors, commercial trajectory is dominated by net pricing and formulary penetration; in mature tadalafil markets, sustained growth is difficult without differentiation that blocks substitution.

Primary revenue drivers

• Persistence of branded differentiation through access and prescribing behavior
• Contract leverage with PBMs
• Ability to defend tier placement with rebates relative to generic tadalafil’s net cost

Primary constraints

• Generic tadalafil price floor limits net pricing for the brand
• Plan formulary evolution during annual updates
• Higher payer sensitivity to total drug spend after generic expansion in the class
• Patient switching after nonpreferred placement increases co-pay exposure

---

What financial metrics should be used to track TLANDO performance?

Featured snippet answer: Net sales trend, gross-to-net ratio, prescription share, and payer mix are the four most informative readouts for a tadalafil brand under generic substitution pressure.

Metric checklist

• Net sales trend by quarter
• Gross-to-net and rebate intensity
• Units and ASP (average selling price) movement
• Prescription volume (Rx) trends
• Payer mix shift (commercial vs Medicare)
• Formulary position changes (preferred tier movement)
• Channel inventory indicators (if disclosed)

How these metrics typically behave under generic pressure

• ASP drops first (rebate and contract changes)
• Units decline after formulary and substitution shifts
• Gross-to-net can rise even as units fall, then stabilize after competitive pricing settles

---

Key takeaways

• TLANDO’s market dynamics are primarily access and rebate-driven in a tadalafil class where generic alternatives set the cost floor.
• Financial trajectory hinges on whether TLANDO maintains protected product differentiation that delays generic AB-substitution, and on how aggressively PBMs and plans shift preferred status toward the lowest net cost option.
• Generic entry risk typically affects revenue via two channels: (1) net pricing compression through contracting and rebates and (2) later unit displacement after broader substitution.
• To forecast TLANDO financially, model the class substitution path using net sales, gross-to-net, and payer mix as leading indicators of formulary behavior and competitive penetration.

---

FAQs

1) What does “AB-rated” substitution mean for a tadalafil brand like TLANDO?
It means an FDA-approved generic product can be substituted at the pharmacy without requiring a new prescription, accelerating unit loss if it is covered and placed favorably in formularies.

2) How do Medicaid and commercial pharmacy benefit design typically affect PDE5 inhibitor branded sales?
Formulary preferences and cost-sharing typically favor the lowest-cost PDE5 option, which tends to increase generic substitution and reduce branded share unless the brand secures preferred status.

3) What are the fastest indicators that TLANDO will face net pricing compression?
Rising gross-to-net ratios, increased rebate payments, and plan formulary movement to nonpreferred tiers often precede visible unit declines.

4) Do method-of-use or formulation patents protect TLANDO from immediate generic entry?
They can if they are listed in the Orange Book for the specific product and are not successfully designed around; otherwise generic substitution can occur once statutory barriers clear.

5) How should investors interpret TLANDO growth that is not accompanied by rising units?
It generally signals that contracting, rebate structures, or pricing mix improved temporarily, while underlying substitution pressure is still present.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm

DrugChatter Q&A for TLANDO

Does medicare cover tlando?